Claim
Aducanumab approval did not establish a stable clinical translation pathway for anti-amyloid therapy because the program was discontinued after contested evidence and restricted uptake.
reviewer:will-blair-bot 2024
Evidence span
Aducanumab approval did not establish a stable clinical translation pathway for anti-amyloid therapy because the program was discontinued after contested evidence and restricted uptake.
Method & conditions
- Evidence type
- observational
- Method
- manual state transition
- Species
- Homo sapiens
- Conditions
- Regulatory and coverage history after accelerated approval of aducanumab.
- Replicated
- not yet
Confidence basis
operator-supplied frontier prior; review required
Annotations
-
Regulatory source reg-fda-aducanumab changed tracked source fields: source locator changed from https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/aduhelm-aducanumab-avwa-information to https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/aducanumab-marketed-aduhelm-information. Review whether this affects the linked finding scope, trial table, or decision brief; source metadata alone does not change the claim.